glp-1 amgen Redefining Obesity Care: The Revolution amgen glp-1 drug A GIPR

doi: 10.2337/db18-1123 3 GasbjergLSHelstedMMHartmannBSparre-UlrichAHVeedfaldSStensenSet al

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION6): a randomised, openlabel study

This includes both true off-label utilization, as well as improper engagement with physicians and care coordination

The overall market size is expected to grow by 8X during the same period, supported by expanding treatment eligibility, increasing public reimbursement coverage, and growing clinical evidence for cardiovascular risk reduction benefits

and BMI at baseline (3035, 3540, and 40 kg/m 2 )

In Type 1 diabetes, insufficient insulin production results from the immune system targeting and destroying the pancreatic beta cells, which are responsible for insulin secretion